Transaction Information
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the closing of an underwritten public offering of units for gross proceeds of approximately $6.0 million, which includes the full exercise of the underwriter's over-allotment option.
Biodexa also announced the closing of its exclusive worldwide license agreement with Melior Pharmaceuticals I, Inc., relating to Tolimidone, a phase II ready Type I Diabetes clinical program.
Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering.
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. For more information visit www.biodexapharma.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.